|
Allele Symbol Allele Name Allele ID |
Tg(TRAMP)8247Ng transgene insertion 8247, Norman M Greenberg MGI:2384595 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary |
27 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Reduced tumor growth in Epn1tm1.1Wami/Epn1tm1.1Wami Epn2tm1Ocr/Epn2tm1Ocr Tg(Cdh5-cre/ERT2)CIVE23Mlia/0 Tg(TRAMP)8247Ng/0 mice
|
• tamoxifen-treated mice exhibit decreased mortality compared with Tg(TRAMP)8247Ng control mice
|
|
• tamoxifen-treated mice develop smaller tumors compared with Tg(TRAMP)8247Ng control mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• tamoxifen-treated mice die at around 36 weeks of age compared with 48 weeks for Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males
|
|
|
• tamoxifen-treated mice exhibit earlier onset of prostate tumor growth compared with Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males
|
|
|
• castration of nude mice transplanted with tumors from tamoxifen-treated mice attenuates tumor growth more than in Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males
|
|
|
• prostate tumors from tamoxifen-treated mice transplanted into nude mice exhibit increased tumor growth compared with tumors from Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males
|
|
|
• tamoxifen-treated mice exhibit earlier onset of prostate tumor growth compared with Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males
|
|
|
• tamoxifen-treated mice exhibit earlier onset of prostate tumor growth compared with Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males
|
|
|
• tamoxifen-treated mice exhibit earlier onset of prostate tumor growth compared with Artm3.1(AR)Ska Tg(TRAMP)8247Ng hemizygous males
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• at 140 days of age the incidence of prostate tumors is increased compared to transgenic mice wild-type for Ahr
• at 210 days of age the total number of lymph node metastases is increased but when normalized for the increased number parent tumors no significant difference is seen
|
|
|
• at 140 days of age the incidence of prostate tumors is increased compared to transgenic mice wild-type for Ahr
• at 210 days of age the total number of lymph node metastases is increased but when normalized for the increased number parent tumors no significant difference is seen
|
|
|
• at 140 days of age the incidence of prostate tumors is increased compared to transgenic mice wild-type for Ahr
• at 210 days of age the total number of lymph node metastases is increased but when normalized for the increased number parent tumors no significant difference is seen
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• at 140 days of age the incidence of prostate tumors is increased compared to transgenic mice wild-type for Ahr
• at 175 days of age the total number of lymph node metastases is increased but when normalized for the increased number parent tumors no significant difference is seen
|
|
|
• at 140 days of age the incidence of prostate tumors is increased compared to transgenic mice wild-type for Ahr
• at 175 days of age the total number of lymph node metastases is increased but when normalized for the increased number parent tumors no significant difference is seen
|
|
|
• at 140 days of age the incidence of prostate tumors is increased compared to transgenic mice wild-type for Ahr
• at 175 days of age the total number of lymph node metastases is increased but when normalized for the increased number parent tumors no significant difference is seen
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• similar to in mice expressing Tg(TRAMP)8247Ng, survival is reduced to 26 to 28 weeks unlike in wild-type mice
|
|
|
• mice develop prostate and genitourinary tract masses unlike wild-type mice but at a 10% reduced occurrence compared to in Tg(TRAMP)8247Ng expressing mice
|
|
|
• mice develop prostate masses unlike wild-type mice but at a 10% reduced occurrence compared to in Tg(TRAMP)8247Ng expressing mice
|
|
|
• mice develop prostate masses unlike wild-type mice but at a 10% reduced occurrence compared to in Tg(TRAMP)8247Ng expressing mice
|
|
|
• mice develop prostate masses unlike wild-type mice but at a 10% reduced occurrence compared to in Tg(TRAMP)8247Ng expressing mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• tumors progress to a highly penetrant invasive prostatic adenocarcinoma unlike in age-matched transgenic mice wild-type for Usp11
|
|
|
• significantly higher rate of high grade prostatic intraepithelial neoplasia compared to transgenic mice wild-type for Usp11
|
|
|
• at 20 weeks of age tumor masses show severe malignant progression unlike in age-matched transgenic mice wild-type for Usp11
• prostatic tumor nodules metastasize to lymph nodes at a higher rate compared to age-matched transgenic mice wild-type for Usp11
|
|
|
• tumor masses are larger at 20 weeks of age compared to transgenic mice wild-type for Usp11
|
|
|
• tumors progress to a highly penetrant invasive prostatic adenocarcinoma unlike in age-matched transgenic mice wild-type for Usp11
|
|
|
• significantly higher rate of high grade prostatic intraepithelial neoplasia compared to transgenic mice wild-type for Usp11
|
|
|
• tumors progress to a highly penetrant invasive prostatic adenocarcinoma unlike in age-matched transgenic mice wild-type for Usp11
|
|
|
• significantly higher rate of high grade prostatic intraepithelial neoplasia compared to transgenic mice wild-type for Usp11
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• significantly delayed prostate tumor formation
• fewer "PIN" lesions at 20 weeks than controls but not significantly
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• the incidence of metastasis to distant solid organs is lower, with only 7% of mice having gross metastasis to solid organs compared to 61% of controls
• primary tumors derived from mutant mice fail to generate metastasis in wild-type recipient mice
• primary tumor cells from mutant donor mice injected into the tibia of recipient hosts results in no tumor development unlike controls that show tumors in the bone
|
|
|
• mice develop prostate tumors that are more than twice as large as in controls
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• at 29 weeks of age, 85% of male transgenic mutant mice had a palpable tumor or had died due to prostate cancer, compared to wild-type transgenic mice; longer Q tract length appears to increase susceptibility to prostate cancer
|
|
|
• at 29 weeks of age, 85% of male transgenic mutant mice had a palpable tumor or had died due to prostate cancer, compared to wild-type transgenic mice; longer Q tract length appears to increase susceptibility to prostate cancer
|
|
|
• at 29 weeks of age, 85% of male transgenic mutant mice had a palpable tumor or had died due to prostate cancer, compared to wild-type transgenic mice; longer Q tract length appears to increase susceptibility to prostate cancer
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| prostate cancer | DOID:10283 |
OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959 |
J:108849 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• at 29 weeks of age, only 28% of transgenic mutant mice had a palpable tumor or had died due to prostate cancer, compared to wild-type transgenic mice: shorter Q tract length confers some protection from prostate cancer
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| prostate cancer | DOID:10283 |
OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959 |
J:108849 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• at 29 weeks of age, 52% of male transgenic mutant mice had a palpable tumor or had died due to prostate cancer, compared to wild-type transgenic mice, comparable to wild-type transgenic mice
|
|
|
• at 29 weeks of age, 52% of male transgenic mutant mice had a palpable tumor or had died due to prostate cancer, compared to wild-type transgenic mice, comparable to wild-type transgenic mice
|
|
|
• at 29 weeks of age, 52% of male transgenic mutant mice had a palpable tumor or had died due to prostate cancer, compared to wild-type transgenic mice, comparable to wild-type transgenic mice
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| prostate cancer | DOID:10283 |
OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959 |
J:108849 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• tumor mass significantly less than in controls at 25 weeks of age
• at 30 weeks of age, both tumor mass and volume are lower than in controls
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• mice aged 21-30 weeks of age develop primary prostate cancers; frequency is comparable to Tbx21-sufficient transgenic mice
• all mice regardless of Tbx21 status develop high-grade prostatic epithelial neoplasia with 96% of Tbx21-sufficient vs 91% of Tbx21-deficient transgenic mice developing overt adenocarcinoma
• Tbx21-deficient transgenics develop a modest but somewhat higher grade adenocarcinomas than Tbx21-sufficient mice
• overall tumor size does not differ significantly between genotypes
|
|
|
• Tbx21-deficient transgenic mice consistently develop increased frequency of metastatic disease in the liver, lung or salivary glands (3/21 Tbx21-sufficient vs 13/25 Tbx21-null transgenics)
• per organ, tissues develop higher rates of metastasis(24% of 88 organs) vs Tbx21-sufficient transgenic mice (6% of 79 organs); metastasis is not seen in non-transgenic Tbx21-sufficient animals but was observed in 1 non-transgenic Tbx21-null mouse with low grade prostatic adenocarcinoma
|
|
|
• mice aged 21-30 weeks of age develop primary prostate cancers; frequency is comparable to Tbx21-sufficient transgenic mice
• all mice regardless of Tbx21 status develop high-grade prostatic epithelial neoplasia with 96% of Tbx21-sufficient vs 91% of Tbx21-deficient transgenic mice developing overt adenocarcinoma
• Tbx21-deficient transgenics develop a modest but somewhat higher grade adenocarcinomas than Tbx21-sufficient mice
• overall tumor size does not differ significantly between genotypes
|
|
|
• mice aged 21-30 weeks of age develop primary prostate cancers; frequency is comparable to Tbx21-sufficient transgenic mice
• all mice regardless of Tbx21 status develop high-grade prostatic epithelial neoplasia with 96% of Tbx21-sufficient vs 91% of Tbx21-deficient transgenic mice developing overt adenocarcinoma
• Tbx21-deficient transgenics develop a modest but somewhat higher grade adenocarcinomas than Tbx21-sufficient mice
• overall tumor size does not differ significantly between genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• mice are moribund with prostrate tumors on average at 34.4 weeks of age
• intraepithelial neoplasia and adenocarcinomas at different stages of differentiation are observed in the prostrate
• there is a increased incidence of metastasis compared to mice that carry just the transgene
|
|
|
• mice are moribund with prostrate tumors on average at 34.4 weeks of age
• intraepithelial neoplasia and adenocarcinomas at different stages of differentiation are observed in the prostrate
• there is a increased incidence of metastasis compared to mice that carry just the transgene
|
|
|
• mice are moribund with prostrate tumors on average at 34.4 weeks of age
• intraepithelial neoplasia and adenocarcinomas at different stages of differentiation are observed in the prostrate
• there is a increased incidence of metastasis compared to mice that carry just the transgene
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• mice are moribund with prostrate tumors on average at 28.6 weeks of age
• intraepithelial neoplasia and adenocarcinomas at different stages of differentiation are observed in the prostrate
• there is a increased incidence of metastasis compared to mice that carry just the transgene (56.5% compared to 33%)
|
|
|
• mice are moribund with prostrate tumors on average at 28.6 weeks of age
• intraepithelial neoplasia and adenocarcinomas at different stages of differentiation are observed in the prostrate
• there is a increased incidence of metastasis compared to mice that carry just the transgene (56.5% compared to 33%)
|
|
|
• mice are moribund with prostrate tumors on average at 28.6 weeks of age
• intraepithelial neoplasia and adenocarcinomas at different stages of differentiation are observed in the prostrate
• there is a increased incidence of metastasis compared to mice that carry just the transgene (56.5% compared to 33%)
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• development of primary prostate tumor growth is significantly impeded in mutants in comparison to Tg(TRAMP)8247Ng hemizygous mice
• development of regional and distant metastasis is attenuated
• tumors derived from mutants exhibit an increase in apoptotic cells compared to cells in Tg(TRAMP)8247Ng hemizygous mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• by 3 months, 50% of mice develop high-grade prostatic intraepithelial neoplasm; by 6 months, only 21.4% of animals have progressed to adenocarcinoma
|
|
|
• prostatic adenocarcinomas and epithelial neoplasms show significantly more apoptotic cells relative to tumors in Tg(TRAMP)8247Ng single transgenic mice
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| prostate cancer | DOID:10283 |
OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959 |
J:125633 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• prostate tumors detectable earlier than in controls, by 10-15 weeks of age
• greater tumor mass than controls until about 20 weeks of age but not thereafter
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• at age 30 weeks
|
|
• substantial tumor formation at age 30 weeks
|
|
• engorged at age 30 weeks
|
|
• at ages 10 and 30 weeks
|
|
• fewer mice live past 30 weeks and increased number die after 30 weeks owing to tumor load
|
|
• at ages 10 and 30 weeks
|
|
• at age 30 weeks
|
|
• substantial tumor formation at age 30 weeks
|
|
• engorged at age 30 weeks
|
|
• at ages 10 and 30 weeks
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice do not exhibit metastasis to the liver and lymph nodes unlike Tg(TRAMP)8247Ng mice
|
|
• reduced tumor volume and weight without evidence of invasive prostatic adenocarcinoma compared with Tg(TRAMP)8247Ng mice
|
| N |
• unlike in Tg(TRAMP)8247Ng mice, prostate histology is normal
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• reduced tumor volume and weight compared with Tg(TRAMP)8247Ng mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• early-arising, massive prostate tumors that weight more than 2.7 grams are three times more frequent in these mice than in littermate controls that carry just the transgene
• the incidence of mice with early arising tumors is 27.9%
• these tumors exhibit nearly uniform lesions of poorly differentiated cells that are highly malignant
• tumors that arise later have cells that are well differentiated and less aggressive
• the mean weight of prostates at necropsy significantly exceeds that of controls
|
|
|
• early-arising, massive prostate tumors that weight more than 2.7 grams are three times more frequent in these mice than in littermate controls that carry just the transgene
• the incidence of mice with early arising tumors is 27.9%
• these tumors exhibit nearly uniform lesions of poorly differentiated cells that are highly malignant
• tumors that arise later have cells that are well differentiated and less aggressive
• the mean weight of prostates at necropsy significantly exceeds that of controls
|
|
|
• early-arising, massive prostate tumors that weight more than 2.7 grams are three times more frequent in these mice than in littermate controls that carry just the transgene
• the incidence of mice with early arising tumors is 27.9%
• these tumors exhibit nearly uniform lesions of poorly differentiated cells that are highly malignant
• tumors that arise later have cells that are well differentiated and less aggressive
• the mean weight of prostates at necropsy significantly exceeds that of controls
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• by 24 weeks, mice show metastatic deposits in pelvic lymph nodes, renal lymph nodes, lungs, salivary glands and liver while TRAMP littermates primarily show deposits in the pelvic lymph nodes
|
|
|
• fewer multi-lobe tumors develop at 18 and 24 weeks (14 and 57% respectively) than in hemizygous TRAMP littermates (45 and 86%, respectively)
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| prostate cancer | DOID:10283 |
OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959 |
J:144539 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• mice are moribund with prostrate tumors on average at 31.4 weeks of age
• intraepithelial neoplasia and adenocarcinomas at different stages of differentiation are observed in the prostrate
|
|
|
• in lesions, basal cells are not disorganized in contrast to Tg(Pbsn-ERG*)1Vv mice at 13 weeks
(J:131932)
(J:133908)
|
|
|
• mice are moribund with prostrate tumors on average at 31.4 weeks of age
• intraepithelial neoplasia and adenocarcinomas at different stages of differentiation are observed in the prostrate
|
|
|
• in lesions, basal cells are not disorganized in contrast to Tg(Pbsn-ERG*)1Vv mice at 13 weeks
(J:131932)
(J:133908)
|
|
|
• mice are moribund with prostrate tumors on average at 31.4 weeks of age
• intraepithelial neoplasia and adenocarcinomas at different stages of differentiation are observed in the prostrate
|
|
|
• in lesions, basal cells are not disorganized in contrast to Tg(Pbsn-ERG*)1Vv mice at 13 weeks
(J:131932)
(J:133908)
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• prostates weigh an average of >6g, while in transgenic mice expressing the Tg(ACTB-SAC/EGFP)35Rang transgene, most (78.5%) prostate glands weigh <2g and remaining 21.5% weigh between 2 and 3 grams
|
|
|
• majority (62.5-83.3%) of mice develop high-grade prostatic intraepithelial neoplasia by 3 months of age and 12-16% of animals show adenocarcinoma of the prostate; by 6 months, all mice develop adenocarcinoma of the prostate
|
|
|
• prostates weigh an average of >6g, while in transgenic mice expressing the Tg(ACTB-SAC/EGFP)35Rang transgene, most (78.5%) prostate glands weigh <2g and remaining 21.5% weigh between 2 and 3 grams
|
|
|
• majority (62.5-83.3%) of mice develop high-grade prostatic intraepithelial neoplasia by 3 months of age and 12-16% of animals show adenocarcinoma of the prostate; by 6 months, all mice develop adenocarcinoma of the prostate
|
|
|
• majority (62.5-83.3%) of mice develop high-grade prostatic intraepithelial neoplasia by 3 months of age and 12-16% of animals show adenocarcinoma of the prostate; by 6 months, all mice develop adenocarcinoma of the prostate
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Histological analysis of prostate tumors in Tg(TRAMP)8247Ng/0 mice
|
|
• males display focal and invasive adenocarcinoma of the prostate by 20 weeks
(J:65303)
• mice exhibit a range of prostate hyperplasia to invasive carcinomas
(J:217920)
• mice treated with bromhexine hydrochloride, a TMPRSS2 inhibitor, at 15 weeks of age and continued to about 20 weeks, show larger prostate glands (ie, larger prostate tumors) than vehicle-treated mice and reduced incidence of distant metastasis to lung and liver from 55% in vehicle-treated mice to 20% with bromhexine hydrochloride
(J:217920)
|
|
|
• intraepithelial hyperplasia can be detected in males by 10 weeks of age and by 22 weeks of age, almost all prostatic glands are hyperplastic
|
|
|
• males display focal and invasive adenocarcinoma of the prostate by 20 weeks
(J:65303)
• mice exhibit a range of prostate hyperplasia to invasive carcinomas
(J:217920)
• mice treated with bromhexine hydrochloride, a TMPRSS2 inhibitor, at 15 weeks of age and continued to about 20 weeks, show larger prostate glands (ie, larger prostate tumors) than vehicle-treated mice and reduced incidence of distant metastasis to lung and liver from 55% in vehicle-treated mice to 20% with bromhexine hydrochloride
(J:217920)
|
|
|
• intraepithelial hyperplasia can be detected in males by 10 weeks of age and by 22 weeks of age, almost all prostatic glands are hyperplastic
|
|
|
• males display focal and invasive adenocarcinoma of the prostate by 20 weeks
(J:65303)
• mice exhibit a range of prostate hyperplasia to invasive carcinomas
(J:217920)
• mice treated with bromhexine hydrochloride, a TMPRSS2 inhibitor, at 15 weeks of age and continued to about 20 weeks, show larger prostate glands (ie, larger prostate tumors) than vehicle-treated mice and reduced incidence of distant metastasis to lung and liver from 55% in vehicle-treated mice to 20% with bromhexine hydrochloride
(J:217920)
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| prostate cancer | DOID:10283 |
OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959 |
J:65303 | |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 05/07/2024 MGI 6.23 |
|
|
|
||
Analysis Tools